Condition: Postprandial Hypoglycemia · Sponsor: University Hospital, Basel, Switzerland
The primary objective of this randomized trial is to test whether a treatment with canakinumab is superior to placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it improves health related quality of life (mentally or physically) or reduces the risk of hypoglycemic events.
This description comes directly from the study's public registry record.
Marc Y Donath, Prof. Dr. · +41 61 265 25 25 · marc.donath@usb.ch
Susanne Ruesch · +41 61 556 5655 · susanne.ruesch@usb.ch
Always discuss trial participation with your own doctor first.
| University Hospital Basel, Division of Endocrinology, Diabetes and Metabolism | Basel, Switzerland | Recruiting |
| Cantonal Hospital Olten, Division of Endocrinology | Olten, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05401578